1499-56-5

Basic information

• Product Name: TRANS-4-HYDROXY-L-PROLINE METHYL ESTER
• Synonyms: TRANS-4-HYDROXY-L-PROLINE METHYL ESTER;L-Proline, 4-hydroxy-, methyl ester, (4R)- (9CI);METHYL(2S,4R)-4-HYDROXYPYRROLIDINE-2-CARBOXYLATE;L-Proline, 4-hydroxy-, Methyl ester, (4R)-;(2R,4S)-METHYL4-HYDROXYPYRROLIDINE-2-CARBOXYLATE;METHYL (2S,4R)-4-HYDROXYPYRROLIDINE-2-CARBOXYLATE(Hydrochloride form);Trans-4-Hydroxy-L-P
• CAS NO: 1499-56-5
• Molecular Formula: C₆H₁₁NO₃
• Molecular Weight: 145.16
• Product Categories: CARBOXYLICESTER;Esters;Pyrrolidines
• Mol File: 1499-56-5.mol
• Article Data: 72

Chemical Properties

• Melting Point: 156-160 °C
• Boiling Point: 247.177°C at 760 mmHg
• Flash Point: 103.289°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 14.44±0.40(Predicted)
• CAS DataBase Reference: TRANS-4-HYDROXY-L-PROLINE METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS-4-HYDROXY-L-PROLINE METHYL ESTER(1499-56-5)
• EPA Substance Registry System: TRANS-4-HYDROXY-L-PROLINE METHYL ESTER(1499-56-5)

Safety Data

• Hazardous Substances Data: 1499-56-5(Hazardous Substances Data)

Usage

Uses

(2S,4R)-Methyl 4-Hydroxypyrrolidine-2-carboxylate is used in preparation of Pyridazinamine derivatives as modulators of SMARCA2 and BRM target proteins.

InChI:InChI=1/C6H11NO3/c1-10-6(9)5-2-4(8)3-7-5/h4-5,7-8H,2-3H2,1H3/t4?,5-/m0/s1

Upstream product

• 186581-53-3 diazomethane 
• 51-35-4 4R-4-hydroxyproline 
• 60-29-7 diethyl ether 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 67-56-1 methanol 
• 3398-22-9 trans-4-hydroxyproline 
• 75-36-5 acetyl chloride 
• 1063998-64-0 (2S,4R)-4-Hydroxy-pyrrolidine-2-carbonyl chloride 
• 2584-71-6 cis-hydroxy-D-proline 

Downstream Products

• 122350-59-8 (2S,4R)-1-(9H-fluoren-9-yl)methyl-2-methyl-4-hydroxypyrrolidine-1,2-dicarboxylate 
• 519189-06-1 (3R,5R)-1-benzyl-3,5-di[(tert-butyldimethylsilyl)oxy]-piperidine 
• 882990-40-1 (3R,5R)-1-benzyl-5-[(tert-butyldimethylsilyl)oxy]-3-trityloxypiperidine 
• 882990-52-5 (2S,4R)-1-benzyl-4-[(tert-butyldiphenylsilyl)oxy]-2-methoxycarbonylpyrrolidine 
• 882990-56-9 (2S,4R)-2-{1-benzyl-4-[(tert-butyldiphenylsilyl)oxy]-pyrrolidinyl}methanol 
• 882990-54-7 (2S,4R)-methyl 1-benzyl-4-((triisopropylsilyl)oxy)pyrrolidine-2-carboxylate 
• 882990-58-1 (2S,4R)-2-{1-benzyl-4-[(triisopropylsilyl)oxy]-pyrrolidinyl}methanol 
• 203866-16-4 1-tert-butyl 2-methyl (2S,4S)-4-fluoropyrrolidine-1,2-dicarboxylate 
• 154429-40-0 (2S,4R)-1-benzyl-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-2-carboxylic acid methyl ester 
• 154343-02-9 (2S,4R)-4-{[1-(tert-butyl)-1,1-dimethylsilyl]-oxy}-1-benzyl-2-hydroxy-methyl-pyrrolidin 
• 161564-09-6 (3R,5R)-1-benzyl-5-[(tert-butyldimethylsilyl)oxy]-piperidin-3-ol 
• 114358-14-4 O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate 

Relevant articles and documents

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

As Aurora kinase inhibitor derivatives

The present invention relates to a substituted pyrazole derivative used for inhibiting Aurora kinase and represented by formula (I) or formula (Ia), or stereo isomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, a medicinal composition containing the above compounds as active ingredients, and a use of the compounds and the medicinal composition in preparation of medicines for protecting, processing, treating or mitigating proliferative diseases of patients.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.